Steven Baumgarten, MD
Critical Care Medicine · Cherry Hill, NJNPI 1528038114
Payments from drug & device makers
Across 532 payments — averaging $16.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$2K
- Mylan Specialty L.p.$512
- Sanofi$491
- Boehringer Ingelheim$350
- Regeneron Healthcare Solutions, Inc.$344
- plus $3K from 34 others
What the payments were for
- Food & beverage$8,726100%
- Education$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 106 | $2,116 |
| GSK | 157 | $1,987 |
| Mylan Specialty L.p. | 36 | $512 |
| Sanofi | 30 | $491 |
| Boehringer Ingelheim | 24 | $350 |
| Regeneron Healthcare Solutions, Inc. | 20 | $344 |
| Inari Medical, Inc. | 2 | $332 |
| Actelion Pharmaceuticals US, Inc. | 15 | $327 |
| United Therapeutics Corporation | 15 | $235 |
| Harmony Biosciences LLC | 14 | $218 |
| Insmed, Inc. | 11 | $164 |
| Philips North America LLC | 10 | $161 |
| Axsome Therapeutics, Inc. | 10 | $156 |
| Novartis | 8 | $126 |
| Verona Pharma, Inc. | 6 | $110 |
| Baxter Healthcare | 4 | $110 |
| Grifols USA, LLC | 7 | $102 |
| Genentech USA, Inc. | 6 | $93 |
| Amgen | 6 | $93 |
| Jazz Pharmaceuticals Inc. | 6 | $91 |
| Teva Pharmaceuticals USA, Inc. | 6 | $88 |
| Merck | 6 | $85 |
| Electromed, Inc. | 3 | $46 |
| Paratek Pharmaceuticals, Inc. | 3 | $40 |
| Inspire Medical Systems, Inc. | 2 | $38 |
| Advanced Respiratory, Inc | 2 | $36 |
| Bayer | 2 | $36 |
| Exact Sciences | 1 | $30 |
| Pulmonx Corporation | 2 | $30 |
| Pfizer | 2 | $29 |
| ANI Pharmaceuticals, Inc. | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Azurity Pharmaceuticals, Inc. | 1 | $19 |
| Resmed Corp | 1 | $18 |
| Lilly USA, LLC | 1 | $18 |
| Pharming Healthcare, Inc. | 1 | $15 |
| Phadia US Inc. | 1 | $15 |
| Viatris Specialty LLC | 1 | $14 |
| Mallinckrodt Enterprises LLC | 1 | $13 |
| AbbVie | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FLOWTRIEVER CATHETER, S$475
- TEZSPIRE$364
- FASENRA$250
- BREZTRI$249
- CT THROMBECTOMY SYSTEM KIT$189
- FARXIGA$140
- AREXVY$125
- UPTRAVI$122
- OPSUMIT$122
- AIRSUPRA$110
How this compares
$8,745 in reported general payments places this provider in the 85th percentile of 254 critical care medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 446 | $391,561 |
| EsbrietPirfenidone | 12 | $128,352 |
| Dupixent PenDupilumab | 24 | $108,304 |
| Breo ElliptaFluticasone/Vilanterol | 164 | $82,653 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 76 | $52,801 |
| EliquisApixaban | 79 | $47,327 |
| Incruse ElliptaUmeclidinium Bromide | 91 | $40,989 |
| NucalaMepolizumab | 11 | $38,143 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 53 | $37,696 |
| Pirfenidone | 11 | $31,094 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 183 | $21,648 |
| Spiriva RespimatTiotropium Bromide | 28 | $16,936 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 400 | $13,894 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $13,211 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 20 | $12,089 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Nucala, Anoro Ellipta | $1,987 | $593,422777 claims |
| Genentech USA, Inc.Esbriet | $93 | $128,35212 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $2,116 | $61,723107 claims |
| PfizerEliquis | $29 | $47,32779 claims |
| Boehringer IngelheimSpiriva Respimat, Combivent Respimat, Stiolto Respimat | $350 | $42,23560 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 254 critical care medicine providers in New Jersey.
Other critical care medicine in Cherry Hill
- Ira HorowitzCherry Hill$7K
- Nicholas RoyCherry Hill$7K
- David BaumgartenCherry Hill$6K
- Fariborz RezaiLivingston$2.4M
- Ronak ShahHackensack$439K
- Eric SztejmanMarlton$231K
- Eric TellerHackensack$217K
- Steven ChangNewark$191K
- Jonathan GalliMarlton$128K
- Keith RoseHackensack$112K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.